drugset / Trial / NCT01122030
Study to Evaluate the Safety and Efficacy of Naldemedine (S-297995) for the Treatment of Opioid-Induced Bowel Dysfunction in Subjects With Chronic Pain
RandomizedSingle-groupTriple-blindTreatment
Summary
The primary objective of the study is to evaluate the safety of single doses of oral naldemedine in adults physically dependent on opioids.
Timeline
- Start
- 2010-05-19
- Primary completion
- 2011-02-23
- Completion
- 2011-03-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Naldemedine | Other / unclassified | 0.01 mg | Oral |
| Subject | Naldemedine | Other / unclassified | 0.03 mg | Oral |
| Subject | Naldemedine | Other / unclassified | 0.1 mg | Oral |
| Subject | Naldemedine | Other / unclassified | 0.3 mg | Oral |
| Subject | Naldemedine | Other / unclassified | 1 mg | Oral |
| Subject | Naldemedine | Other / unclassified | 3 mg | Oral |